Supplementary material: Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims

These are peer-reviewed supplementary materials for the article 'Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: Mean (SD) number of inpatient admissions per patient in individuals with SMA in the 12 months before and after nusinersen treatment. Mean (SD) number of days spent in hospital per patient in individuals with SMA in the 12 months before and after nusinersen treatment.Supplementary Figure 2: Mean (SD) ED visits and costs per patient in individuals with SMA in the 12 months before and after nusinersen treatment.Supplementary Table 1: Patient baseline characteristics of cohorts aligned with steps of patient selection criteria (who were ultimately excluded) in comparison to final cohort.Aim: Nusinersen, administered by intrathecal injection at a dose of 12 mg, is indicated across all ages for the treatment of spinal muscular atrophy (SMA). Evidence on real-world healthcare resource use (HRU) and costs among patients taking nusinersen remains limited. This study aimed to evaluate real-world HRU and costs associated with nusinersen use through US claims databases. Patients & methods: Using the Merative™ MarketScan R ? Research Databases, patients with SMA receiving nusinersen were identified from commercial (January 2017 to June 2020) and Medicaid claims (January 2017 to December 2019). Those likely to have complete information on the date of nusinersen initiation and continuous enrollment 12 months pre- and post-index (first record of nusinersen treatment) were retained. Number and costs (US$ 2020) of inpatient admissions and emergency department (ED) visits, unrelated to nusinersen administration, were evaluated for 12 months pre- and post-nusinersen initiation and stratified by age: pediatric (

本数据集为发表于《比较有效性研究杂志》的论文《在nusinersen治疗后，评估脊髓性肌萎缩症（SMA）患者住院及急诊部门医疗资源利用和成本的前后变化：基于美国索赔数据》的同行评审补充材料。补充图1：SMA患者在接受nusinersen治疗前后的12个月内，每位患者的平均（标准差）住院次数。SMA患者在接受nusinersen治疗前后的12个月内，每位患者的平均（标准差）住院天数。补充图2：SMA患者在接受nusinersen治疗前后的12个月内，每位患者的平均（标准差）急诊就诊次数及费用。补充表1：与患者选择标准步骤相匹配的队列患者的基线特征（最终被排除在外）与最终队列的比较。研究目的：nusinersen通过鞘内注射给药，剂量为12 mg，适用于所有年龄段SMA的治疗。关于使用nusinersen的患者在真实世界中的医疗资源利用（HRU）和成本的证据仍然有限。本研究旨在通过美国索赔数据库评估使用nusinersen的真实世界HRU和成本。患者与方法：利用Merative™ MarketScan R ? 研究数据库，从商业（2017年1月至2020年6月）和医疗补助索赔（2017年1月至2019年12月）中确定了接受nusinersen治疗的SMA患者。保留了那些可能具有关于nusinersen起始日期和索引日期（nusinersen治疗的第一条记录）前后连续入组12个月完整信息的患者。评估了与nusinersen给药无关的住院次数和急诊部门（ED）就诊次数及其成本（2020年美元），时间范围为nusinersen起始前后各12个月，并按年龄分层：儿科（<18岁）、青少年（18-30岁）和成人（≥30岁）。